GSK appoints Mr Urs Rohner to its Board as a Non-Executive Director
6 October 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the appointment of Mr Urs Rohner to its Board as a Non-Executive Director, effective 1 January 2015...
List view / Grid view
News
Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb’s novel immunotherapy in combination treatments for NSCLC
6 October 2014 | By Novartis
Novartis announced that it has entered into a clinical collaboration with Bristol-Myers Squibb Company to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor...
Bristol-Myers Squibb and MD Anderson Cancer Center announce novel research collaboration in immuno-oncology focused on leukemia and hematologic malignancies
6 October 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center announced a novel clinical research collaboration to evaluate multiple immunotherapies...
Fast diagnosis: New mobile lab helps MOH fight infectious disease during Hajj
6 October 2014 | By The Ministry of Health
The Ministry of Health has installed a Biosafety Level 3 (BSL-3) mobile lab outside East Arafat Hospital as part of its public-health preparedness program for Hajj...
CleveXel Pharma to license two new oncology patents from SATT Sud Est
6 October 2014 | By CleveXel Pharma
They will address the treatment of bone marrow cancers and the diagnosis of patients who are resistant to standard treatments...
OBN celebrates the stars of UK Life Sciences
3 October 2014 | By OBN
OBN revealed last night the winners of its Annual Awards celebrating the best of UK life sciences – the innovators, fundraisers and dealmakers who underline the pre-eminence of the UK sector in the global marketplace...
Allied-Bristol Life Sciences appoints Satish Jindal to lead the discovery of drug candidates from leading academic institutions
3 October 2014 | By Allied-Bristol Life Sciences
Allied-Bristol Life Sciences today announced that Satish Jindal, Ph.D., formerly Vice President of R&D within Bristol-Myers, has been appointed to lead the company’s efforts to identify and foster development of biopharmaceutical innovations from top U.S. university research institutions...
Agar Scientific appoints Paul Balaş as new Technical Sales Manager
3 October 2014 | By Agar Scientific
Paul joins Agar Scientific from Ronexprim SRL – where he was an Executive Director and the Area Sales Manager for PANalytical X-ray equipment and FEI electronic microscopes in Romanian territories...
Lilly to discontinue development of Tabalumab based on efficacy results in phase 3 lupus studies
2 October 2014 | By Eli Lilly and Company
Eli Lilly and Company announced today it will discontinue development of tabalumab -- being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) -- due to insufficient efficacy in two pivotal Phase 3 trials. The decision was not based on safety concerns. ..
rfC included in the new draft 5.1.10 by the European Pharmacopeia
News from the European Pharmacopoeia:
Bristol-Myers Squibb to announce results for Third Quarter on October 24
2 October 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company will announce results for the third quarter on Friday, October 24, 2014...
Thermo Scientific TGA-IR Module enhances materials characterization for users of FT-IR Spectrometers
Scientists involved in materials characterization, process validation and product failure analysis can gather more valuable data by combining two powerful analytical techniques. The new Thermo Scientific TGA-IR Module provides users of Thermo Scientific FT-IR spectrometers with enhanced performance when combining Thermal Gravimetric Analysis (TGA) and FT-IR spectroscopy.
Daiichi Sankyo and Daiichi Sankyo Espha submit supplemental New Drug Application in Japan for “Cravit® Tablets, Granules” and “Levofloxacin Tablets, Granules DSEP”
1 October 2014 | By Daiichi Sankyo
Daiichi Sankyo Company Limited announced that it and its domestic generic subsidiary, Daiichi Sankyo Espha Co., Ltd. have submitted a supplemental New Drug Application (sNDA) in Japan...
Asthma: Spiriva® (tiotropium) Respimat® becomes the only LAMA licensed in asthma care
1 October 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that adult asthma patients could benefit from a new treatment...
Cardio3 BioSciences announces new business development strategy to broaden its product pipeline
1 October 2014 | By Cardio3 BioSciences
Cardio3 BioSciences announces that it has recently increased its business development activities, building on its core expertise in cellular therapies and in cardiovascular diseases...
